Human African trypanosomiasis presenting at least 29 years after infection--what can this teach us about the pathogenesis and control of this neglected tropical disease? [PDF]
No abstract ...
Francesco Checchi +38 more
core +1 more source
Untargeted metabolomics reveals a lack of synergy between nifurtimox and eflornithine against trypanosoma brucei [PDF]
A non-targeted metabolomics-based approach is presented that enables the study of pathways in response to drug action with the aim of defining the mode of action of trypanocides.
Burgess, K. +34 more
core +1 more source
Trypanosoma brucei rhodesiense transmitted by a single tsetse fly bite in vervet monkeys as a model of human African trypanosomiasis [PDF]
Sleeping sickness is caused by a species of trypanosome blood parasite that is transmitted by tsetse flies. To understand better how infection with this parasite leads to disease, we provide here the most detailed description yet of the course of ...
Thuita, J.K. +20 more
core +1 more source
Estimates of the duration of the early and late stage of gambiense sleeping sickness
Background: The durations of untreated stage 1 (early stage, haemo-lymphatic) and stage 2 (late stage, meningo-encephalitic) human African trypanosomiasis (sleeping sickness) due to Trypanosoma brucei gambiense are poorly quantified, but key to ...
Filipe, João AN +21 more
core +1 more source
Chemotherapy of Human African Trypanosomiasis
Human Africa trypanosomiasis is a centuries-old disease which has disrupted sub-Saharan Africa in both physical suffering and economic loss. This article presents an update of classic chemotherapeutic agents, in use for >50 years and the recent ...
Cyrus J. Bacchi
doaj +1 more source
Early prediction of treatment efficacy in Second-Stage Gambiense Human African Trypanosomiasis
Human African trypanosomiasis is fatal without treatment. The long post-treatment follow-up (24 months) required to assess cure complicates patient management and is a major obstacle in the development of new therapies.
Chappuis, F. +23 more
core +1 more source
Genotypic status of the TbAT1/P2 adenosine transporter of Trypanosoma brucei gambiense isolates from northwestern Uganda following melarsoprol withdrawal [PDF]
Human African trypanosomiasis (HAT) manifests as a chronic infection caused by <i>Trypanosoma brucei gambiense</i>, or as a more acute form due to <i>T. b. rhodesiense</i>.
Barbara Nerima +23 more
core +1 more source
Patients with second-stage human African trypanosomiasis treated with eflornithine (n = 251) in 2003 in Kiri, southern Sudan, had an adjusted relative risk of death of 0.2 and experienced significantly fewer cutaneous and neurological adverse effects ...
Chappuis, F +4 more
core +1 more source
Introduction: The development of neurological disorders following trypanosome brain infection has been recognised for over a century. However, an ongoing endeavour persists to comprehensively understand the neurocognitive and neuropathological changes ...
Dr Oluwashola Olaolu +7 more
doaj +1 more source
Risk for Human African Trypanosomiasis, Central Africa, 2000–2009
Comprehensive georeference records for human African trypanosomiasis in Cameroon, Central African Republic, Chad, Congo, Equatorial Guinea, and Gabon were combined with human population layers to estimate a kernel-smoothed relative risk function.
Pere P. Simarro +8 more
doaj +1 more source

